Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mirum Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MIRM
Nasdaq
8731
https://mirumpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
- May 13th, 2024 1:40 pm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 10th, 2024 11:30 pm
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss
- May 10th, 2024 5:55 pm
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
- May 9th, 2024 3:46 pm
Q1 2024 Mirum Pharmaceuticals Inc Earnings Call
- May 9th, 2024 11:40 am
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...
- May 9th, 2024 7:49 am
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- May 8th, 2024 8:02 pm
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- May 7th, 2024 8:10 pm
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
- May 7th, 2024 12:30 pm
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
- May 2nd, 2024 5:34 pm
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- May 1st, 2024 8:10 pm
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
- Apr 30th, 2024 2:01 pm
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Apr 25th, 2024 2:02 pm
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Apr 2nd, 2024 12:30 pm
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
- Mar 29th, 2024 3:30 pm
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
- Mar 26th, 2024 3:46 am
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Mar 25th, 2024 11:00 am
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
- Mar 15th, 2024 1:32 pm
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mar 13th, 2024 10:00 pm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Mar 5th, 2024 1:00 pm
Scroll